SAVA News & Events

Cassava Sciences announced the rebranding of the Company, with a name change to Filana Therapeutics. The new name and corporate brand reflect the Company's strategic focus on developing novel medicines to modulate the filamin A protein for the treatment of central nervous system disorders, such as Tuberous Sclerosis Complex-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. The Company will begin trading under the new ticker symbol "FLNA" on the Nasdaq Capital Market at the open of the market on March 11, 2026. "The launch of Filana Therapeutics represents a new beginning for our Company. Growing evidence suggests that filamin A is an important regulator of neuronal development and that modulating filamin A may provide a new approach to treating CNS disorders such as TSC-related epilepsy. Centering our identity on filamin A reflects our dedication to rigorous scientific discovery and to bringing new treatment options to patients and their families," said Rick Barry, CEO.

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump with this daily recap compiled by The Fly.DOJ PROBE:The Department of Justice has summoned large theater chains to discuss the potential impact of a sale of Warner Bros. Discovery, with government antitrust lawyers seeking information on how a sale would impact the movie-going public and film releases in theaters, Bloomberg's Thomas Buckley. The Justice Department's review is focused on the potential impact of a sale to either Netflixor Paramount Skydanceon the cinema industry, people familiar with the matter say.BOARD OF PEACE:JPMorganis in discussions to provide banking services to the U.S.-backed "Board of Peace," an institution aimed at supporting Gaza's reconstruction and positioned by Donald Trump as a potential alternative to the United Nations, The Financial Times' Neri Zilber, James Shotter, Joshua Franklin, and Abigail Hauslohner. The initiative is part of a broader effort to establish a new governance framework for Gaza following the two-year war between Israel and Hamas. According to two people familiar with the situation, the bank is discussing providing services such as facilitating payments to and from the board.INVESTIGATION CLOSURE:Cassava Sciencesannounced that the U.S. Department of Justice Fraud Section has closed its inquiry into the company regarding allegations of research misconduct. That indictment was dismissed with prejudice by DOJ on October 23, 2025. As previously disclosed, the company reached a settlement with the U.S. Securities and Exchange Commission of negligence-based disclosure charges in September 2024 and paid a monetary penalty without admitting or denying the SEC's allegations. The company cooperated fully with both the DOJ and SEC investigations. These outcomes end the investigations of the company by the DOJ and SEC.CASE CAN PROCEED:U.S. District Judge Arun Subramanian ruled that Live Nationmust face an antitrust trial from Department of Justice and various states for allegedly monopolizing the live events market. Subramanian ruled that a jury should see evidence and decide whether Live Nation's conduct in the concert business amounts to illegal monopolization.

Cassava Sciences announced that the U.S. Department of Justice Fraud Section has closed its inquiry into the Company regarding allegations of research misconduct as described in the indictment in United States v. Wang, 8:24-cr-000211-TDC. That indictment was dismissed with prejudice by DOJ on October 23, 2025. As previously disclosed, the Company reached a settlement with the U.S. Securities and Exchange Commission of negligence-based disclosure charges in September 2024 and paid a monetary penalty without admitting or denying the SEC's allegations. The Company cooperated fully with both the DOJ and SEC investigations. These outcomes end the investigations of the Company by the DOJ and SEC.

Cassava Sciences announced publication of the article Phase 3 randomized clinical trials of simufilam in mild-to-moderate Alzheimer's disease in an upcoming issue of the Journal of Prevention of Alzheimer's Disease, JPAD. The paper provides a detailed analysis of data from two Phase 3 clinical trials, RETHINK-ALZ and REFOCUS-ALZ. While, as previously disclosed, the two studies did not meet their pre-specified co-primary, secondary, or exploratory biomarker endpoints, exploratory post-hoc analysis of the studies offers informative insights. "In keeping with our commitment to report the detailed results, we are pleased to make the data from the RETHINK-ALZ and REFOCUS-ALZ studies available to the Alzheimer's disease scientific community through publication in the highly respected Journal of Prevention of Alzheimer's Disease. We hope the paper can serve as a foundation for further research in the field," said Rick Barry, President and Chief Executive Officer of Cassava. "The detailed safety observations reported in the article provide heartening encouragement for our ongoing development program in TSC-related epilepsy, as we work to initiate a proof-of-concept study in collaboration with leading investigators."